Core Viewpoint - The announcement details a significant partnership and investment involving昊海生物科技,亨泰光学, and亨泰视觉, which includes exclusive distribution rights and equity acquisition, indicating a strategic move to enhance market presence in the optical lens sector [1][2]. Group 1: Exclusive Distribution Agreement -昊海生物科技's subsidiary,昊海控股, has signed an exclusive distribution agreement with亨泰光学 and亨泰视觉 for high-end orthokeratology contact lenses "迈儿康myOK" in mainland China for a duration of 10 years, expiring on December 31, 2030 [1]. - The agreement also grants昊海控股 exclusive distribution rights for children's myopia management optical lenses "贝视得" in mainland China [1]. Group 2: Equity Acquisition -昊海发展, another subsidiary of昊海生物科技, has entered into an investment agreement to acquire a 55% stake in亨泰视觉 for RMB 25 million, making亨泰视觉 a controlled subsidiary and included in the consolidated financial statements of the company [1]. - Following a change in control of亨泰光学 due to a proposed acquisition by Carl Zeiss Vision International GmbH,昊海控股 and亨泰光学's major shareholders have signed a termination agreement for the existing cooperation [2]. - As part of the termination agreement,亨泰光学's major shareholders will pay昊海控股 a termination compensation of RMB 80 million [2].

Core Viewpoint - The company has entered into exclusive distribution agreements and investment agreements with Hengtai Optical and Hengtai Vision, which will significantly impact its market position in the high-end contact lens sector in China [1][2]. Group 1: Exclusive Distribution Agreements - The company’s wholly-owned subsidiary, Haohai Biotechnology Holdings, signed an exclusive distribution agreement with Hengtai Optical and Hengtai Vision for the high-end orthokeratology contact lens product "myOK" in mainland China for a duration of 10 years, expiring on December 31, 2030 [1]. - The agreement also includes the exclusive distribution rights for Hengtai Vision's optical lenses for children's myopia management, named "Beishide," in mainland China [1]. Group 2: Investment Agreement - The company’s subsidiary, Haohai Pharmaceutical Technology Development, has signed an investment agreement to acquire a 55% stake in Hengtai Vision for RMB 25 million, making Hengtai Vision a subsidiary and consolidating it into the company's financial statements [1]. Group 3: Termination of Existing Cooperation - Due to Carl Zeiss Vision International's intention to acquire 100% of Hengtai Optical, the existing cooperation between Haohai Holdings and Hengtai Optical will be terminated, with a compensation payment of RMB 80 million to Haohai Holdings [2]. - Following the termination, Hengtai Vision will transfer 45% of its shares from its minority shareholder to Haohai Development, making Hengtai Vision a wholly-owned subsidiary of Haohai Development [2].